Opko Health, Inc.
- Last sale
- Nov 12, 2026 · -3.49%
- Market cap
- $1.23B
- 742.51M shares
- Filings
- 1,037
Q3 2026−14.9% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−14.6% FY25 yoy
- $1.23B
- —
- 2.5×
- 1.1×
- -10.98%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $606,879,000 | reported | |
| FY 2024 | 2024-12-31 | $713,142,000 | reported | |
| FY 2023 | 2023-12-31 | $863,495,000 | reported | |
| FY 2022 | 2022-12-31 | $1,004,196,000 | reported | |
| FY 2021 | 2021-12-31 | $1,774,718,000 | reported | |
| FY 2020 | 2020-12-31 | $1,435,413,000 | reported | |
| FY 2019 | 2019-12-31 | $901,935,000 | reported | |
| FY 2018 | 2018-12-31 | $990,266,000 | reported | |
| FY 2017 | 2017-12-31 | $966,006,000 revised | reported | |
| FY 2016 | 2016-12-31 | $1,117,494,000 revised | reported | |
| FY 2015 | 2015-12-31 | $491,738,000 | reported | |
| FY 2014 | 2014-12-31 | $91,125,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $47.04M | $47.04M | — | 759.07M sh | +13.0% | — |
| FY2024 | — | $90.22M | $90.22M | — | 671.55M sh | −3.7% | — |
| FY2023 | — | $0.00 | $0.00 | — | 696.99M sh | −9.8% | — |
| FY2022 | — | $0.00 | $0.00 | — | 772.65M sh | +13.4% | — |
| FY2013 | — | $0.00 | $0.00 | — | 412.92M sh | +27.3% | — |
Segments
LineFY2025ShareChange
Diagnostics$21.26M—N/M
Pharmaceuticals-$98.34M—N/M
Total-$117.41M
Pharmaceutical preparations
Opko Health, Inc. is the 50th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
KNSAKiniksa Pharmaceuticals International, plc$677.6M60.1%8.7%$15.1BRAREUltragenyx Pharmaceutical Inc.$673.0M20.2%85.4%$1.6BAXSMAxsome Therapeutics, Inc.$638.5M65.5%28.7%$7.6BTGTXTG Therapeutics, Inc.$616.3M87.3%72.6%$9.8B
OPKOpko Health, Inc. (this company)$606.9M14.9%37.2%$1.2B
INSMInsmed Inc$606.4M66.7%210.5%$25.9BORGOOrganogenesis Holdings Inc.$564.2M17.0%6.6%$125.3MHCMHUTCHMED (China) Ltd$548.5M13.0%83.3%$2.6BMIRMMirum Pharmaceuticals, Inc.$521.3M54.7%4.5%$6.1BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Opko Health, Inc. · CIK 944809 · Engraved from SEC EDGAR